Welcome to our dedicated page for Ibio news (Ticker: IBIO), a resource for investors and traders seeking the latest updates and insights on Ibio stock.
iBio, Inc. (NASDAQ: IBIO) is an AI-driven biotechnology company developing precision antibody therapies for cardiometabolic diseases, obesity, cancer and other hard-to-treat conditions. The IBIO news feed on Stock Titan aggregates company press releases and other coverage so readers can follow how the business and its preclinical pipeline are evolving over time.
Recent news highlights iBio’s focus on obesity and cardiometabolic disease, including preclinical data for its Activin E antibody candidate IBIO-610 and its long-acting anti-myostatin antibody IBIO-600. The company has reported fat-selective, GLP‑1‑synergistic weight loss in diet-induced obesity mouse models, non-human primate pharmacokinetic data suggesting extended half-life and potential for infrequent dosing, and early evidence that its programs may help preserve lean mass in combination with GLP‑1 therapies. Updates also cover presentations at scientific and investor conferences such as ObesityWeek, PEGS Europe and healthcare-focused investment conferences.
Investors tracking IBIO news will also see announcements about financings, including underwritten public offerings, warrant transactions and private placements with institutional investors, along with disclosures on how proceeds are intended to support preclinical cardiometabolic programs and other pipeline assets. Regulatory and corporate developments reported via Form 8‑K, such as Nasdaq listing compliance notices, annual meeting results and updated corporate presentations, provide additional context on governance and capital markets activity.
By following this IBIO news page, readers can monitor new preclinical data, conference participation, financing transactions and key SEC-reported events that shape iBio’s progress as a preclinical-stage, AI-enabled antibody developer.
iBio (NASDAQ:IBIO) announced a private placement expected to raise approximately $26 million gross, led by Frazier Life Sciences with participation from existing healthcare-focused institutional investors. The offering is expected to close on or about January 13, 2026, subject to customary conditions. iBio will sell 11,061,738 shares of common stock (or pre-funded warrants) at $2.35 per share (or $2.349 per pre-funded warrant). Proceeds are intended to advance preclinical cardiometabolic programs including IBIO-610, IBIO-600, and myostatin/activin A bispecific programs, and to fund other pipeline work and working capital. The financing extends iBio’s cash runway into calendar 2028. The securities were offered to accredited investors in a Regulation D/Section 4(a)(2) placement; iBio agreed to file registration statements covering resale.
iBio (NASDAQ: IBIO) will participate in the 8th Annual Evercore Healthcare Conference in Miami, December 2–4, 2025. Martin Brenner, DVM, Ph.D., CEO and Chief Scientific Officer, will appear in a fireside chat on Thursday, December 4, 2025 at 8:45 a.m. ET to discuss iBio’s progression of its next‑generation obesity pipeline toward clinical development and recent non‑human primate data for IBIO‑610 presented at ObesityWeek 2025.
Felipe Duran, CFO, will be available for one‑on‑one meetings during the conference. A livestream will be available and a replay link will be posted on the company’s Investor website.
iBio (NASDAQ:IBIO) reported Q1 fiscal 2026 results and a corporate update on Nov 12, 2025. Key highlights include a closed $50.0M underwritten public offering of pre-funded warrants and common warrants with up to $100.0M potential gross proceeds if common warrants are fully exercised, and cash, cash equivalents and debt investments of $49.6M as of Sept 30, 2025, which the company says supports operations into the fourth quarter of fiscal 2027.
iBio presented non-human primate data for IBIO-610 showing a predicted human half-life up to 100 days, consistent with dosing as infrequent as twice per year, and preclinical evidence of fat-selective, GLP-1–synergistic weight-loss and sustained weight maintenance.
iBio (NASDAQ: IBIO) reported new preclinical data for IBIO-610, an Activin E antibody for fat-selective weight loss and maintenance. In obese non-human primates, IBIO-610 showed an extended half-life of 33.2 days. Using allometric scaling, iBio projects a predicted human half-life up to 100 days, potentially enabling dosing as infrequently as once every six months. Prior mouse data reportedly showed fat-selective, GLP-1-synergistic weight loss and prevention of weight regain after GLP-1 discontinuation. The NHP pharmacokinetic data and mechanistic preclinical results will be presented at ObesityWeek 2025.
iBio (NASDAQ: IBIO) will participate in the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston on November 10–12, 2025. CEO and Chief Scientific Officer Martin Brenner, DVM, Ph.D. will appear in a fireside chat on November 10, 2025 at 8:30 a.m. ET to discuss iBio's progress toward becoming a clinical-stage biotechnology company and updates on its next-generation obesity antibody pipeline. CFO Felipe Duran will be available for one-on-one meetings during the conference. A livestream will be available, and a replay link will be posted on the Investor section of iBio's website.
iBio (NASDAQ:IBIO) will present new preclinical data on its Activin E antibody, IBIO-610, at two scientific conferences in November 2025. Cory Schwartz, Ph.D. will deliver an oral presentation at ObesityWeek on Nov 4, 2025 and a poster on Nov 5. Martin Brenner, DVM, Ph.D. will present at PEGS Europe on Nov 12, 2025. The company highlights non-human primate data suggesting fat-selective weight loss, potential support for long-term weight maintenance, and possible synergy with GLP-1 therapies.
iBio (NASDAQ:IBIO) reported its fiscal year 2025 results and corporate updates, highlighting significant progress in its cardiometabolic and obesity pipeline. The company's lead candidates include IBIO-610, an activin E-targeting antibody showing 26% fat mass reduction without lean mass loss, and IBIO-600, a long-acting anti-myostatin antibody demonstrating extended half-life and dose-dependent muscle growth.
Financial highlights include revenue of $0.4M (up $0.2M YoY), R&D expenses of $8.3M (up $3.1M), and G&A expenses of $10.7M (down $1.0M). The company strengthened its position through a $50M public offering with potential for additional $50M from warrant exercises. iBio successfully transferred to Nasdaq trading and expanded its leadership team with industry veterans.
iBio (Nasdaq: IBIO) has successfully closed its previously announced public offering, raising initial gross proceeds of $50 million. The offering included pre-funded warrants to purchase 71,540,000 shares and accompanying Series G and H warrants. If all warrants are exercised, iBio could receive an additional $50 million in gross proceeds.
The offering was led by Balyasny Asset Management with participation from several prominent investors. The proceeds will be used to advance iBio's preclinical cardiometabolic programs, including IBIO-610 and IBIO-600, through key development milestones. Leerink Partners served as the lead bookrunner, with LifeSci Capital and Oppenheimer & Co. as bookrunning managers.
The Series G warrants are linked to a Trial Initiation Milestone and will expire either 30 trading days after the milestone announcement or five years from issuance, while Series H warrants have a four-year term.iBio (Nasdaq: IBIO) has announced the pricing of a $50 million public offering of pre-funded warrants and accompanying Series G warrants. The offering includes 71,540,000 pre-funded warrants to purchase common stock and Series G warrants to purchase 35,770,000 shares, along with Series H warrants.
The combined offering price is set at $0.699 per unit, with Series G and H warrants having an exercise price of $0.70 per share. If all warrants are exercised, iBio could receive additional gross proceeds of approximately $50 million. The company plans to use the proceeds to advance its preclinical cardiometabolic programs, including IBIO-610 and IBIO-600, and fund working capital requirements.
[ "Potential total gross proceeds of up to $100 million if all warrants are exercised", "Funds will advance key preclinical cardiometabolic programs IBIO-610 and IBIO-600", "Multiple tier-1 investment banks involved in the offering including Leerink Partners as lead bookrunner" ]iBio (Nasdaq: IBIO), an AI-driven precision antibody therapies company, has announced a proposed underwritten public offering. The offering includes pre-funded warrants to purchase common stock and accompanying Series G and Series H warrants.
The company plans to use the proceeds to advance its preclinical cardiometabolic programs, including IBIO-610 (myostatin and activin A bispecific) and IBIO-600 programs, as well as other preclinical pipeline assets. Leerink Partners is leading the offering as the lead bookrunning manager, with LifeSci Capital and Oppenheimer & Co. serving as additional bookrunning managers.
FAQ
What is the current stock price of Ibio (IBIO)?
What is the market cap of Ibio (IBIO)?
